Lehrstuhl für Haut- und Geschlechtskrankheiten

A systems biology approach to characterize the function of miRNAs in dendritic cell-mediated immunogenicity and therapeutic cancer vaccination (2017) Lai X, Dreyer F, Jaitly T, Gerer KF, Schuler G, Dörrie J, Schaft N, Vera J Conference contribution BRAF and MEK inhibitors influence human immune cell phenotype and function (2017) Hoyer S, Eberlein V, Babalija L, Gerer KF, Walter L, Schuler G, Schaft N, et al. Conference contribution Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Data from the PROSPECT Study on Psoriasis Pre-treatment (2017) Von Kiedrowski R, Korber A, Kraehn-Senftleben G, Sticherling M, Lange L, Bachhuber T, Kasparek TR, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without previous Systemic Therapy for Improvement of Skin Symptoms: PASI and IGA mod. 2011-Results of the PRIME Study (2017) Reich K, Mrowietz U, Augustin M, Thaci D, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with respect to the Improvement of quality of life: DLQI and SF-36 Results of the PRIME Study (2017) Augustin M, Thaci D, Reich K, Mrowietz U, Kneidl J, Hentschke C, Simang M, et al. Conference contribution The delivery of antigens to dendritic cells is a potent futureoption for anti-tumor therapies (2017) Lehmann C, Heger L, Neubert K, Harzer C, Amon L, Yamazaki S, Heidkamp GF, et al. Conference contribution The distribution of C-type lectin receptors in the Dendritic cell membrane (2017) Lühr J, Eissing N, Heidkamp GF, Lehmann CHK, Heger L, Dudziak D Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with regard to compatibility-related Therapeutic Adherence: Safety Results of the PRIME Study (2017) Mrowietz U, Augustin M, Thaci D, Reich K, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis with without previous Systemic Therapy for Improvement of Nail Symptoms: NAPSI Results PRIME Study (2017) Thaci D, Reich K, Mrowietz U, Augustin M, Kneidl J, Hentschke C, Simang M, et al. Conference contribution The simultaneous siRNA-mediated downregulation of inhibitory receptors to improve CAR-T cell immunotherapy of melanoma (2017) Simon B, Harrer D, Weide B, Schuler G, Schuler-Thurner B, Dörrie J, Schaft N, Uslu U Conference contribution